- Home
- ALXO vs ORIS Comparison
ALXO vs ORIS Comparison
Compare ALXO & ORIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- ORIS
- Stock Information
- Founded
- ALXO 2015
- ORIS 2014
- Country
- ALXO United States
- ORIS China
- Employees
- ALXO N/A
- ORIS N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- ORIS Farming/Seeds/Milling
- Sector
- ALXO Health Care
- ORIS Consumer Staples
- Exchange
- ALXO Nasdaq
- ORIS Nasdaq
- Market Cap
- ALXO 24.0M
- ORIS 19.5M
- IPO Year
- ALXO 2020
- ORIS 2024
- Fundamental
- Price
- ALXO $0.48
- ORIS $0.94
- Analyst Decision
- ALXO Strong Buy
- ORIS
- Analyst Count
- ALXO 6
- ORIS 0
- Target Price
- ALXO $3.30
- ORIS N/A
- AVG Volume (30 Days)
- ALXO 397.6K
- ORIS 71.9K
- Earning Date
- ALXO 08-07-2025
- ORIS 02-21-2025
- Dividend Yield
- ALXO N/A
- ORIS N/A
- EPS Growth
- ALXO N/A
- ORIS N/A
- EPS
- ALXO N/A
- ORIS 0.17
- Revenue
- ALXO N/A
- ORIS $15,014,000.00
- Revenue This Year
- ALXO N/A
- ORIS N/A
- Revenue Next Year
- ALXO N/A
- ORIS N/A
- P/E Ratio
- ALXO N/A
- ORIS $5.57
- Revenue Growth
- ALXO N/A
- ORIS N/A
- 52 Week Low
- ALXO $0.41
- ORIS $0.82
- 52 Week High
- ALXO $8.78
- ORIS $56.01
- Technical
- Relative Strength Index (RSI)
- ALXO 44.63
- ORIS N/A
- Support Level
- ALXO $0.48
- ORIS N/A
- Resistance Level
- ALXO $0.59
- ORIS N/A
- Average True Range (ATR)
- ALXO 0.05
- ORIS 0.00
- MACD
- ALXO -0.00
- ORIS 0.00
- Stochastic Oscillator
- ALXO 8.75
- ORIS 0.00
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About ORIS Oriental Rise Holdings Limited Ordinary Shares
Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).